AbbVie's 2.62% Stock Surge Driven by ASH 2025 Data and FDA Approval Pushes Trading Volume to $1.12 Billion Ranking 83rd in U.S. Equity Market

Market Snapshot

AbbVie’s stock (ABBV) rose 2.62% on December 3, 2025, with a trading volume of $1.12 billion, ranking it 83rd in the U.S. equity market by daily volume. The gain followed a series of high-impact announcements related to its oncology pipeline, including new data from clinical trials and regulatory approvals. The stock’s performance reflects investor optimism about AbbVie’s advancing blood cancer treatments and its expanding role in hematologic malignancies.

Key Drivers: ASH 2025 Data and FDA Approval Boost Confidence

AbbVie’s stock surge was primarily driven by the company’s presentation of novel clinical data at the 2025 American Society of Hematology (ASH) Congress, highlighting progress in blood cancer therapies. The firm showcased results from a Phase 1b/2 trial of PVEK (pivekimab sunirine) combined with venetoclax and azacitidine (VEN + AZA) in newly diagnosed, CD123-positive acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. The regimen achieved a 63.3% complete remission (CR) rate in 49 participants, a significant outcome for a patient population with limited treatment options. While adverse events like neutropenia and thrombocytopenia were common, the data underscored the regimen’s potential to address unmet needs in AML, a key focus area for AbbVie’s oncology division.

The company also highlighted results from the EPCORE FL-1 Phase 3 trial of epcoritamab (EPKINLY) in combination with rituximab and lenalidomide (R2) for relapsed or refractory follicular lymphoma (FL). The trial demonstrated a 79% reduction in the risk of disease progression or death compared to standard R2 therapy, with a hazard ratio (HR) of 0.21. The overall response rate (ORR) and progression-free survival (PFS) improvements were statistically significant, supporting epcoritamab’s potential to redefine treatment paradigms in FL. These findings, presented at ASH, reinforced AbbVie’s leadership in bispecific T-cell engager (BiTE) technology and its broader pipeline of innovative therapies.

Regulatory milestones further contributed to the stock’s upward momentum. The U.S. Food and Drug Administration (FDA) approved EPKINLY + R2 for relapsed or refractory FL in November 2025, based on the EPCORE FL-1 data. This approval expanded AbbVie’s commercial footprint in hematologic cancers, with the combination therapy now available to patients who had received at least two prior treatments. Additionally, a Biologics License Application (BLA) for PVEK was submitted to the FDA for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and aggressive blood cancer. These regulatory advancements signaled to investors that AbbVie is effectively translating clinical innovation into market access, a critical factor for long-term growth.

The broader oncology landscape also played a role in AbbVie’s performance. The ASH 2025 congress served as a platform to emphasize the company’s diverse pipeline, spanning T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates (ADCs). For instance, data on venetoclax-based treatments and etentamig (ABBV-383) demonstrated durable responses and safety profiles across multiple hematologic malignancies. These developments align with AbbVie’s strategy to address the heterogeneity of blood cancers through a multi-modal approach, positioning it as a key player in next-generation therapies. Analysts noted that the company’s ability to generate robust clinical data and secure regulatory approvals in high-growth areas like lymphoma and leukemia strengthens its competitive positioning against peers such as Roche and Bristol-Myers Squibb.

Investor sentiment was further bolstered by AbbVie’s geographic diversification and market dominance in key therapeutic areas. While the U.S. accounts for 76.4% of its net sales, the company’s pipeline advancements—particularly in Europe and Japan—suggest expanding international opportunities. The approval of epcoritamab in Japan for relapsed or refractory FL in August 2025 marked a strategic expansion, making it the first subcutaneous T-cell engager authorized in the region for this indication. Such milestones, combined with the company’s strong cash flow from established products like Humira (despite its patent expiration), reassure investors of AbbVie’s ability to sustain growth despite competitive pressures.

The stock’s 2.62% gain on December 3, 2025, thus reflects a confluence of factors: groundbreaking clinical data, regulatory approvals, and a diversified pipeline targeting high-unmet-need oncology indications. These developments not only validate AbbVie’s R&D capabilities but also reinforce its position as a leader in the evolving blood cancer treatment landscape. As the ASH 2025 congress highlighted, AbbVie’s focus on innovation and patient-centric therapies is likely to drive continued investor confidence and market share gains in the coming years.